Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSHR | P23945 | 18/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323786 | 0.88 | FSHR (1.00) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL2194197 | 0.88 | FSHR (0.82) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL3525399 | 0.87 | FSHR (0.70) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL3525394 | 0.87 | FSHR (0.69) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL1323159 | 0.83 | FSHR (1.00) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL1323199 | 0.82 | FSHR (1.00) | FSHRTSHR | |
| SCHEMBL1323414 | 0.80 | FSHR (0.84) | FSHR | |
| SCHEMBL1323792 | 0.79 | FSHR (1.00) | FSHRTSHR | |
| SCHEMBL3704579 | 0.78 | FSHR (0.67) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL2192397 | 0.77 | HDAC1 (0.51) | FSHRMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | N.V. ORGANON | 2011-07-14 | — | — | US | claimed |
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | N.V. ORGANON | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | TSHR, MC1R, TRHR | FSHR 21/4885TSHR 1/4885MEN1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.